The goal of this clinical trial is to compare the effects of electrical dry needling versus glucosamine sulfate iontophoresis on pain intensity level, functional ability, and knee range of motion in chronic unilateral knee osteoarthritis patients.

开始日期2024-06-01

申办/合作机构

Horus University

NCT06200415 / Completed临床2期IIT

Glucosamine Sulphate Versus Ginger as an Adjunctive Local Delivery Agents in Non-Surgical Periodontal Therapy (A Randomized Controlled Clinical Trial With Biochemical Analysis)

Glucosamine (GlcN) is an N-deacetyl amino monosaccharide sugar derived from complete hydrolysis of chitosan in which it is important vector for chondroitin and keratin sulfate, while on the other hand, medicinal plants became a source of great economic benefit worldwide, ginger has been found to have biological activities such as antioxidant, anti-inflammatory, antimicrobial, and anticancer activities. So, these effects which made it a good candidate to be used in periodontal therapy. The main objective of this study is to assess and compare the effect of locally delivered glucosamine sulphate gel versus ginger gel on the clinical parameters in periodontitis patients including Plaque index (PI), Means sulcus bleeding index (MSBI), Probing depth (PD), Clinical attachment loss (CAL). and to detect the effect of locally delivered both gels on RANKL level in gingival crevicular fluid.

开始日期2022-11-08

申办/合作机构

Ain Shams University

IRCT20220115053712N2 / Completed临床2期IIT

Comparative analysis of Proprioceptive Exercises with and without Topical Glucosamine Sulfate on Pain and Functional Disability in Knee Osteoarthritis

开始日期2021-12-15

申办/合作机构-

100 项与硫酸氨基葡萄糖相关的临床结果

登录后查看更多信息

100 项与硫酸氨基葡萄糖相关的转化医学

登录后查看更多信息

100 项与硫酸氨基葡萄糖相关的专利（医药）

登录后查看更多信息

436

项与硫酸氨基葡萄糖相关的文献（医药）

2025-01-01·JOURNAL OF COLLOID AND INTERFACE SCIENCE

Glucosamine sulfate-loaded nanofiber reinforced carboxymethyl chitosan sponge for articular cartilage restoration

Article

作者: Li, Mingguang ; Ma, Shuai ; Li, Xinzhi ; Zhang, Li ; Wang, Xianguo ; Xia, Haibin ; Liu, Fangtian ; Wu, Yang ; Fan, Yifeng ; Deng, Hongbing ; Huang, Wei

Cartilage is severely limited in self-repair after damage, and tissue engineering scaffold transplantation is considered the most promising strategy for cartilage regeneration. However, scaffolds without cells and growth factors, which can effectively avoid long cell culture times, high risk of infection, and susceptibility to contamination, remain scarce. Hence, we developed a cell- and growth factor-dual free hierarchically structured nanofibrous sponge to mimic the extracellular matrix, in which the encapsulated core-shell nanofibers served both as mechanical supports and as long-lasting carriers for bioactive biomass molecules (glucosamine sulfate). Under the protection of the nanofibers in this designed sponge, glucosamine sulfate could be released continuously for at least 30 days, which significantly accelerated the repair of cartilage tissue in a rat cartilage defect model. Moreover, the nanofibrous sponge based on carboxymethyl chitosan as the framework could effectively fill irregular cartilage defects, adapt to the dynamic changes during cartilage movement, and maintain almost 100 % elasticity even after multiple compression cycles. This strategy, which combines fiber freeze-shaping technology with a controlled-release method for encapsulating bioactivity, allows for the assembly of porous bionic scaffolds with hierarchical nanofiber structure, providing a novel and safe approach to tissue repair.

2024-11-01·JOURNAL OF ORAL REHABILITATION

Can treatment with chondroitin and glucosamine sulphate prevent changes in the articular disc caused by temporomandibular joint osteoarthritis?

Article

作者: Quevedo, Alexandre Silva ; Malaguez, Giulia Giacomini ; Puricelli, Edela ; Artuzi, Felipe Ernesto ; Ponzoni, Deise

Abstract:

Background:

Chondroitin and glucosamine sulphates (CGS) are considered structure‐modifying drugs and have been studied in the prevention, delay or reversal of structural morphological changes in joints caused by osteoarthritis.

Objective:

The aim of the present study was to investigate the action of CGS on the progression of chemically induced osteoarthritis in the temporomandibular joint (TMJ) of rabbits by evaluating the serum levels of tumour necrosis factor (TNF‐α) and collagen in the articular discs.

Materials and Methods:

A sample of 36 male rabbits was divided into three groups: control (CG), osteoarthritis (OG) and treatment (TG). The disease was induced by intra‐articular injection of sodium monoiodoacetate (10 mg/mL) in the OG and TG groups bilaterally. After 10 days, the TG animals received subcutaneous injection of chondroitin sulphates and glucosamine (7.5 mg/kg) and the OG and CG received saline solution (50 μL). Euthanasia times were subdivided into 40 and 100 days. Collagen quantification was performed by biochemical and histological analysis and for the quantification of serum levels of TNF‐α, an enzyme immunoassay was used.

Results:

The TG showed an increase in the collagen area of the articular disc when compared to the CG and the OG. The increase collagen concentration in the discs did not show a statistically significant difference between the groups. Post‐treatment TNF‐α levels were significantly lower in TG compared to OG.

Conclusions:

The results indicate that CGS treatment delayed the degeneration of the collagen in the TMJ articular disc and reduced serum TNF‐α levels, indicating a preventive effect on OA progression.

2024-09-01·POULTRY SCIENCE

Effects of dietary glucosamine sulfate sodium on early laying performance and eggshell quality of laying hens

Article

作者: Wang, Ying ; Zhou, Panhong ; Shi, Xiaoli ; Lu, Shengtao ; Wen, Guanglin ; Guo, Yuming ; Lin, Jiale ; Huang, Yanhua

This study was conducted to determine the influence of dietary glucosamine sulfate sodium (GSS) on laying performance, blood profiles, eggshell and inner quality of eggs and relative expression of the genes related to eggshell in laying hens at early stage. A total of 640 twenty-weeks-old Lohmann laying hens were randomly allotted to 4 treatments with 10 replicates of 16 hens each. The experiment lasted for 8 wk, and dietary treatments were: 1) CON, basal diet; 2) G1, CON + 0.2% GSS; 3) G2, CON + 0.4% GSS; 4) G3, CON + 0.6% GSS. The inclusion of GSS increased average daily feed intake, laying rate, and egg mass (P < 0.05) linearly during wk 21 to 25, 25 to 29, and 21 to 29, egg weight during wk 21 to 25 and 25 to 29, and improved (P < 0.05) feed conversion ratio linearly during wk 21 to 25. The supplementation of GSS increased (P < 0.05) albumen height quadratically, Haugh unit, calcium content, calcium mass, phosphorus content and phosphorus mass linearly at the end of 25th and 29th wk. At the end of 29th wk, the eggshell strength, eggshell weight, eggshell ratio, and eggshell thickness were increased (P < 0.05) linearly in GSS treatments compared with CON. The addition of GSS increased (P < 0.05) serum calcium, estrogen 2, and calcitonin, while decreased (P < 0.05) serum tartrate resistant acid phosphatase (TRAP), parathormone, IL-6 and prostaglandin E₂ (PGE₂) at the end of 29th wk. The inclusion of GSS increased (P < 0.05) the relative expression of ovocalyxin-32 and ovocalyxin-36 linearly at the end of 29th wk, and ovalbumin, osteopontin, calbindin 1, and ovocleidin-116 linearly at the end of 25th and 29th wk. Quadratic effects were observed (P < 0.05) in the laying rate during wk 21 to 25, serum TRAP and PGE₂, the relative expression of ovocleidin-116 at the end of 29th wk. In summary, the inclusion of GSS up-regulated relative expression of osteopontin, ovocleidin-116, ovocalyxin-32 and ovocalyxin-36 in uterus, promoted the serum PGE₂ and calcitonin, thus increased the calcium content of eggshell and finally enhanced eggshell quality.

项与硫酸氨基葡萄糖相关的新闻（医药）

2024-10-21

·华润三九

华润三九“硫酸氨基葡萄糖胶囊”获批

10月9日，华润三九“硫酸氨基葡萄胶囊”（0.25克-以硫酸氨基葡萄糖计或0.314克-以硫酸氨基葡萄糖氯化钠计）获得国家药品监督管理局批准上市，适应症为原发性及继发性骨关节炎。该品种注册分类为化药4类（仿制药，视同通过仿制药质量与疗效一致性评价）。氨基葡萄糖是一种天然的氨基单糖，是蛋白多糖合成的前体物质，可以刺激软骨细胞产生有正常多聚体结构的蛋白多糖，提高软骨细胞的修复能力，抑制损伤软骨的酶如胶原酶和磷酯酶A2，并可防止损伤细胞的超氧化自由基的产生，可以促进软骨基质的修复和重建，从而可延缓骨关节疼痛的病理过程和疾病的进程，改善关节活动，缓解疼痛。此次硫酸氨基葡萄糖胶囊的获批是华润三九自我诊疗创新计划取得又一成果，丰富了公司骨科产品管线。公司将继续高度重视高质量医药健康产品创新研发，持续投入深化创新实力。

一致性评价上市批准

2024-08-28

·药融云

最新批件！44个品种过评，福元医药、人福药业、浙江亚太药业……

注：本文不构成任何投资意见和建议，以官方/公司公告为准；本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及），不代表平台立场。任何文章转载需要得到授权。据NMPA官网，2024年8月27日发布的药品批准证明文件送达信息，44个品种（65品规）通过/视同通过一致性评价，涉及福元医药、人福药业、浙江亚太药业等多家药企。截图来源：NMPA官网本次批件中，从过评的品种来看，有玻璃酸钠滴眼液、地夸磷索钠滴眼液、间苯三酚注射液、硫酸氨基葡萄糖胶囊、乳果糖口服溶液4个品种均有两家药企同日过评。从企业来看，石家庄四药、山东新时代药业、北京福元医药3家药企均有2个品种同日过评。此外，美阿沙坦钾片、盐酸罗匹尼罗缓释片、注射用盐酸地尔硫䓬3个品种为首家过评。更多过评信息详情见下方表格及小程序。 8.27过评品种（标红为首家过评）数据来源：药融云过评药品汇总数据库 END 近期热门资源获取后台回复关键词“报告”，获取数十篇药融云出品独家报告后台回复关键词“2023首仿”，获取2023年首仿药物获批名单后台回复“GLP-1深度报告”，获取完整《GLP-1产业现状与未来发展》PDF版。后台回复“中国 I 类新药”，获取完整《中国 I 类新药靶点》PDF版。后台回复“NAFLD/NASH”，获取完整《NAFLD/NASH报告》PDF版。后台回复“AI+制药”，获取完整《中国AI制药企业白皮书》PDF版。后台回复“XXG”，获取完整《中国心血管系统药物分析报告》PDF版。后台回复“FZZJ”，获取完整《基于剂型改良的复杂注射剂分析》PDF版。后台回复“药品进出口”，获取完整《中国药品进出口白皮书》深度报告-PDF版联系我们，体验药融云更多专业服务会议合作园区服务数据库咨询定制服务媒体合作点击阅读原文，申请药融云企业版免费试用！

一致性评价

2024-08-22

·米内网

中药龙头发威！2个独家品种涨逾100%，25款1类新药来势汹汹，10款新药冲线在即

精彩内容日前，天士力开发的创新药注射用重组人尿激酶原新适应症报产。作为国内现代中药龙头企业，天士力坚持创新驱动，目前有16款中药新药、13款化药/生物药新药步入临床阶段，其中有10款已处于III期临床及以上阶段，上市可期；仿制药方面，22个品种过评/视同过评，8个品种以新分类申报在审（3个暂无首仿）。手握22个独家品种！2个中成药涨超100% 以中药产品起家的天士力成立于1994年，2002年8月在上海证券所挂牌上市。通过多年布局，公司围绕心脑血管、消化代谢、抗肿瘤三大治疗领域，构建涵盖现代中药、化学药及生物药的完善的多层次的产品组合，并快速推进研发创新转型。米内网数据显示，目前国内仅天士力拥有生产批文的品种有22个（以药品名称计，不含原料药），涉及17个中成药，4个化学药以及1个生物药，涵盖心脑血管系统、消化系统、呼吸系统、妇科、儿科等多个治疗领域。国内仅天士力拥有批文的品种注：标*为国家医保品种来源：米内网中国上市药品（MID）数据库天士力以复方丹参滴丸带动了养血清脑颗粒（丸）、芪参益气滴丸、注射用益气复脉、注射用丹参多酚酸等系列独家品种，构建了以心脑血管用药为主的现代中药大药体系。米内网数据显示，近年来在中国三大终端六大市场（统计范围详见本文末）在心脑血管中成药厂家排名中，天士力均名列前茅。在呼吸系统中成药领域，天士力拥有3款独家品种，其中穿心莲内酯滴丸、痰咳净滴丸2024第一季度在中国零售药店终端（城市实体药店+网上药店）的销售额增速均超过100%。作为国内现代中药龙头企业，近年来天士力产品管线逐渐步入收获期。近五年来（2019-2023年），公司有芍麻止痉颗粒、坤心宁颗粒2款中药1类新药（按新版中药注册管理办法，下同）获批生产，安体威颗粒、九味化斑丸、芪苓温肾消囊颗粒3款中药1类新药以及TSL-0319胶囊、JS1-1-01片、TSL-1806胶囊、B1962注射液、重组抗EGFR全人单克隆抗体注射液、培重组人成纤维细胞生长因子21注射液6款化药/生物药1类新药获批临床，复方丹参滴丸、芪参益气滴丸新适应症获批临床；此外，他达拉非片、吉非替尼片、米诺膦酸片、苯扎贝特缓释片、注射用替莫唑胺、盐酸美金刚缓释胶囊、注射用硼替佐米、注射用尼可地尔、利伐沙班片9个品种获批生产并视同过评，其中米诺膦酸片、苯扎贝特缓释片为首仿+首家过评。 2024年以来，天士力研发进展不断：中药新药方面，枇杷清肺饮颗粒、温经汤颗粒2款3.1类新药（古代经典名方中药复方制剂）提交NDA，其中枇杷清肺饮颗粒为国内首家；注射用重组人尿激酶原新适应症提交NDA，推测适应症为急性缺血性脑卒中。化学药方面，1类新药人脐带间充质干细胞注射液获批临床；盐酸达泊西汀片获批生产并视同过评，碳酸司维拉姆片、米诺地尔搽剂、硫酸氨基葡萄糖胶囊3个品种以新分类报产；富马酸酮替芬片、尼可地尔片2个品种通过一致性评价，注射用盐酸地尔硫卓提交一致性评价补充申请。猛攻3大千亿市场！10款新药上市可期近年来，天士力坚定实施创新驱动战略，持续加大研发投入。2023年公司研发投入13.15亿元，同比增长29.49%，占医药工业收入比例为17.73%。2024年第一季度研发费用（不含资本化投入）接近2亿元，同比增长超过20%。通过多年布局，天士力围绕心脑血管、消化代谢、抗肿瘤三大治疗领域，稳步推动现代中药、生物药、化学药研发进展。米内网数据显示，2023年中国三大终端六大市场心脑血管（化药+生物药+中成药）、消化代谢（化药+生物药+中成药）、肿瘤免疫（化药+生物药+中成药）3大类药物销售额合计均超过2000亿元。目前天士力有29款新药（不含已有批文品种开展新适应症，不含终止或暂停临床品种）在国内处于获批临床及以上阶段。从药物类型看，16款为中成药，8款为治疗用生物制品，5款为化学药；从注册分类看（按新版药品注册管理办法），1类新药有25款，2类改良型新药有2款，古代经典名方中药复方制剂有2款。天士力国内在研新药来源：米内网综合数据库在中药新药方面，古代经典名方中药复方制剂枇杷清肺饮颗粒及温经汤颗粒均已申报上市，安神滴丸（失眠症）、脊痛宁片（脊柱关节炎）、青术颗粒（原发性急性痛风性关节炎）、安体威颗粒（风寒感冒）、香橘乳癖宁胶囊（乳腺增生）、苏苏小儿止咳颗粒（儿童感冒咳嗽）、连夏消痞颗粒（功能性消化不良）均处于III期临床试验阶段，上市可期。在化学药及生物药新药方面，PXT3003治疗腓骨肌萎缩症已完成III期全部病例入组，上市可期。此外，安美木单抗（EGFR单抗）、TSL-1502胶囊（PARP抑制剂）、TG1050、JS1-1-01片已处于II期临床试验阶段。仿制药方面，截至目前，天士力有21个品种过评/视同过评，其中7个为首家过评，米诺膦酸片、苯扎贝特缓释片为国内首仿，且目前仍为独家品种。国采方面，公司有5个品种中选，他达拉非片、吲达帕胺片、注射用替莫唑胺等品种在国采落地执行后市场份额攀升。天士力已过评品种注：带*为首家/独家过评，加粗为国采中标来源：米内网一致性评价进度数据库目前天士力还有8个品种以新分类申报在审（含联合申报），其中巴氯芬口服溶液、酒石酸匹莫范色林胶囊、左舒必利片暂无国产仿制药获批，盐酸丙卡特罗口服溶液仅3家企业拥有生产批文。天士力新分类申报且在审的品种来源：米内网中国申报进度（MED）数据库强强联合！天士力易主华润变身国企 8月4日晚间，天士力公告称，公司控股股东天士力集团及其一致行动人，拟通过协议转让的方式，向华润三九转让所持有天士力28%的股份，转让总价为62.12亿元。同时，天士力集团拟通过协议转让的方式，向国新投资转让其所持有天士力5%的股份，转让总价为11.09亿元。交易完成后，天士力控股股东将由天士力集团变更为华润三九，实际控制人将变更为中国华润。 8月5日，天士力复牌，开盘涨停，收涨5.68%，这是资本市场对此次交易的积极反应。有业内人士表示，中药作为我国独特的医疗资源，具有悠久的历史和丰富的临床经验，天士力作为一家以中药为主的企业，与华润三九有着良好的合作基础，这使得华润医药能够进一步扩大其在中药领域的市场份额和影响力。在公告中，华润三九明确表示，此次交易有利于其加快补充创新中药管线，持续深耕中药全流程开发体系，且交易双方也将因此发挥中药产业链协同效应，在中药材种植、创新研发、智能制造、渠道营销等领域相互赋能，增强全产业链核心竞争力。对于天士力来说，公司拥有多个独家品种，在医院端和学术营销方面具有一定优势，而华润三九在医药制造和商业领域处于行业领先地位，双方战略布局优势互补，产业链协同效应有望显现，推进新产品上市和研发成果市场化进程。同时，与国新投资的合作将优化资源配置，有望推动拓宽创新中药管线布局。近年来，国资入主民营中药企业的情况并不鲜见，目前中药上市公司市值TOP10中，高达70%的企业具有国资背景，包括片仔癀、云南白药、华润三九、同仁堂、白云山、东阿阿胶等。在业内看来，一方面，近年来国家出台了系列利好中医药发展的政策，中医药产业的战略价值不断提升；另一方面，中医药企业因国家保护品种、保密配方、老字号、专利等因素具备相当高的进入门槛，其本身掌握着一些稀缺资源，构建了强大的竞争力；此外，中医药产品生命周期长，有些还具有消费品特性，经营波动性小，更易受到偏好稳健的国资青睐。资料来源：米内网数据库、公司公告等注：米内网《中国三大终端六大市场药品竞争格局》，统计范围是：城市公立医院和县级公立医院、城市社区中心和乡镇卫生院、城市实体药店和网上药店，不含民营医院、私人诊所、村卫生室，不含县乡村药店；上述销售额以产品在终端的平均零售价计算。数据统计截至8月21日，如有疏漏，欢迎指正！本文为原创稿件，转载请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092 【分享、点赞、在看】点一点不失联哦

申请上市临床3期上市批准

100 项与硫酸氨基葡萄糖相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D08023	硫酸氨基葡萄糖	M01AX05	-

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
骨关节炎	-	Rottapharm SpA	1982-01-01

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
膝关节炎	临床3期	葡萄牙	Rottapharm SpA	2000-05-01
膝关节炎	临床3期	西班牙	Rottapharm SpA	2000-05-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT00955552 (Artico, CTgov)	临床3期	膝关节炎	100	Cosamin DS® (Nutramax)	鏇願積鬱壓膚積繭淵遞(顧淵餘齋網獵憲膚獵遞) = 築醖範獵範夢艱餘醖觸醖窪網鬱築觸壓製繭醖 (鑰願獵憲蓋範蓋構製蓋, 襯襯遞蓋壓觸膚糧選顧 ~ 壓鏇蓋襯鏇遞齋簾糧鑰) 更多	-	2023-02-08
EULAR2008	N/A	髋关节炎	222	Glucosamine sulphate	齋齋範鏇壓構顧醖網顧(窪鏇構觸醖蓋齋鏇憲淵) = 蓋觸餘壓糧夢網築齋壓製壓廠築齋製鬱積糧淵 (壓構餘窪遞構鏇願齋願, [-8.19 ~ 1.28])	-	2008-06-11
ISRCTN25438351 (not provided, Pubmed)	N/A	膝关节炎	95	Glucosamine sulfate	夢蓋憲觸艱壓壓蓋糧糧(蓋鹹觸膚糧壓餘襯鑰繭) = 夢網壓製憲壓觸餘廠醖鑰鬱憲醖餘膚範願醖網 (網壓築鏇窪夢製獵獵範 )	-	2007-10-31
NCT00110474 (Pubmed)	临床3期	膝关节炎	-	Glucosamine sulfate 1,500 mg	觸鹹願廠選鏇淵廠構繭(憲範淵鏇齋醖網顧鹽衊) = 製壓構齋艱鹽鹽遞衊窪窪齋範廠構糧窪獵糧鬱 (製壓膚餘鏇餘衊鏇糧餘, -2.3, ~ 0.8) 更多	积极	2007-02-01
				Acetaminophen 3 gm/day	觸鹹願廠選鏇淵廠構繭(憲範淵鏇齋醖網顧鹽衊) = 鬱廠顧鬱簾鏇醖壓製窪窪齋範廠構糧窪獵糧鬱 (製壓膚餘鏇餘衊鏇糧餘, -1.9 ~ 0.3) 更多
NCT00032890 (GAIT, Pubmed \| Br Dent J)	临床3期	膝关节炎	1,583	Glucosamine	衊網鏇醖鏇鹽夢遞願壓(膚顧鹹糧壓願壓鬱網鬱) = 憲窪鹽願膚顧壓鏇醖憲憲鹽齋膚廠廠醖衊鏇簾 (鬱齋夢衊鹹糧衊簾積壓 )	不佳	2006-02-23
				Chondroitin sulfate	衊網鏇醖鏇鹽夢遞願壓(膚顧鹹糧壓願壓鬱網鬱) = 醖鹹觸繭餘衊糧衊遞蓋憲鹽齋膚廠廠醖衊鏇簾 (鬱齋夢衊鹹糧衊簾積壓 )
EULAR2005	N/A	膝关节炎	215	Glucosamine Sulfate 1500 mg + Chondroitin Sulfate 1200 mg	齋壓遞壓糧衊簾鹹網鬱(鏇簾鹹鬱襯衊窪餘鑰襯) = 構構齋膚糧餘願齋簾鏇鹹築憲繭窪遞夢廠積繭 (築餘選製製遞範顧鏇簾 ) 更多	-	2005-06-08
3-year trial in knee osteoarthritis (EULAR2005)	N/A	膝关节炎	136	Glucosamine sulfate	廠築壓艱繭窪夢顧餘遞(製餘淵積鏇淵醖廠餘觸) = 壓範鹹蓋鬱膚衊簾構製齋壓衊製構遞鬱憲齋餘 (製觸觸簾壓鏇獵觸醖壓, 0.03 ~ 0.31) 更多	积极	2005-06-08
				Placebo	廠築壓艱繭窪夢顧餘遞(製餘淵積鏇淵醖廠餘觸) = 網築築構鏇繭鏇壓蓋鏇齋壓衊製構遞鬱憲齋餘 (製觸觸簾壓鏇獵觸醖壓, -0.19 ~ 0.07) 更多
EULAR2002	N/A	骨关节炎	319	Glucosamine sulfate	簾窪鹹艱範壓製膚夢鏇(夢膚淵範衊鹹願窪膚艱) = 鏇鹽襯膚襯構顧鏇鏇鏇淵鹽顧艱廠膚簾淵齋鬱 (襯淵膚獵遞觸築鬱壓築 ) 更多	积极	2002-06-12
				Placebo	餘遞遞鬱衊鑰壓鬱壓築(簾淵衊廠鬱選選淵艱願) = 淵構簾範夢淵廠糧窪憲選鑰築積範築齋範齋夢 (觸製壓製壓醖壓艱製繭 ) 更多
EULAR2001	N/A	骨关节炎	202	Glucosamine sulfate 1500 mg	觸憲繭窪鏇膚鹽憲淵鹽(膚範製鬱廠網壓鑰鏇積) = 膚積衊淵蓋壓夢鹽鬱膚醖範憲壓製鬱製願壓獵 (糧膚蓋餘鏇鑰衊網獵鏇, 0.14) 更多	积极	2001-06-13
				Placebo	觸憲繭窪鏇膚鹽憲淵鹽(膚範製鬱廠網壓鑰鏇積) = 築顧鹽膚夢鏇築醖齋範醖範憲壓製鬱製願壓獵 (糧膚蓋餘鏇鑰衊網獵鏇, 0.16) 更多